KMB

Business Context and Reporting Period

Company: Kimberly-Clark Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2007
Business Overview: The Corporation operates four global business segments: Personal Care, Consumer Tissue, K-C Professional & Other, and Health Care. The company is executing a multi-year strategic cost reduction plan aimed at streamlining operations and investing in growth opportunities.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 9.7% in Q3 and 8.6% for the nine months ended September 30, 2007. Growth was driven by volume increases (approx. 5% in Q3), improved net selling prices, and favorable foreign currency effects (approx. 3%).
• Profitability: Operating profit rose 29.7% in Q3 and 30.6% for the nine-month period. A primary driver was a significant reduction in strategic cost reduction charges ($100 million lower in Q3 2007 vs. 2006; $340 million lower for the nine months).
• Segment Performance:
  • Personal Care: Sales up 12.0% (Q3) and 10.8% (9M); Operating profit up 19.5% (Q3) and 18.4% (9M).
  • Consumer Tissue: Sales up 10.5% (Q3); Operating profit declined 7.8% (Q3) due to raw material inflation and higher marketing costs.
  • Health Care: Sales down 5.2% (Q3) due to the exit from the latex exam glove business and lower face mask sales compared to the prior year.
• Cost Inflation: Raw material costs increased approximately $70 million in Q3, driven by higher fiber and nonwoven costs, partially offset by cost savings initiatives.

Guidance, Outlook, and Risks

• Strategic Cost Reductions: The company expects cumulative pretax charges of $875 million to $925 million by the end of 2008. The plan targets annual pretax savings of at least $350 million in 2009. Full-year 2007 pretax charges are expected to total approximately $120 million.
• Capital Allocation: The company reaffirmed its commitment to repurchase $2.8 billion of common stock in 2007. In Q3, it executed an Accelerated Share Repurchase (ASR) of $2 billion and repurchased additional shares in the open market. Capital spending for 2007 is expected to be at the high end of the $900 million to $1 billion range.
• Outlook: Management expects top-line momentum to remain positive, driven by developing and emerging markets and targeted growth in Personal Care and K-C Professional. The company anticipates overcoming inflationary pressures through cost reduction efforts.
• Risks and Contingencies:
  • Tax Uncertainty: Adoption of FIN 48 resulted in a $34.2 million decrease in retained earnings. Approximately $490 million of unrecognized tax benefits remain, with transfer pricing being the most significant uncertainty.
  • Raw Materials: Fluctuations in the prices of fiber, pulp, and oil-based materials pose a risk to margins.
  • Health Care Transition: Sales of exam gloves declined over 20% in Q3 as the company transitions customers from latex to nitrile gloves; supply constraints and competitive conditions remain risks.

Investor Verification Checklist

• Debt Levels: Verify the impact of the $2 billion ASR financing on interest expense and leverage ratios, as total debt increased by approximately $2.2 billion year-over-year.
• Health Care Segment: Monitor the transition from latex to nitrile gloves to ensure sales growth compensates for the volume decline in the latex category.
• Cost Savings Realization: Track the realization of the targeted $350 million annual pretax savings from the strategic cost reduction plan against ongoing raw material inflation.
• Tax Liabilities: Review the status of the $490 million in unrecognized tax benefits and potential settlements related to transfer pricing.
• Share Count: Confirm the dilutive impact of the accelerated share repurchase program on future earnings per share calculations.